News Search Results
Apr 24, 2025, 17:31 ET IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight
landscape, including clinical and non-clinical stage products, and the key metastatic breast cancer companies, including Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd.,
More news about: DelveInsight Business Research, LLP
Apr 24, 2025, 15:32 ET Hammes celebrates two project milestones at Moffitt Cancer Center SPEROS FL
open in January 2026, Moffitt's new Speros campus is a global innovation hub targeting cancer care, research and biotechnology. Hammes is serving as program manager for the campus' new 120,000-square-foot outpatient and proton facility, as well as the new 240,000-square-foot
More news about: Hammes
Apr 24, 2025, 12:00 ET VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
April 24, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing innovative treatments for ocular diseases, today announced positive topline results
More news about: VivaVision Biotech
Apr 24, 2025, 11:00 ET Primo's Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.
TAIPEI, April 24, 2025 /PRNewswire/ -- Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration
More news about: Primo Biotechnology Co., Ltd.
Apr 24, 2025, 10:32 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Apr 24, 2025, 10:01 ET At-Home Genetic Testing Market to Reach $4.5 Bn By 2027 in the short run and $20.2 Bn By 2035 Globally, at 20.3% CAGR: Allied Market Research
potential health risks and tailor lifestyle and treatment plans accordingly. Further, rising investment in research and development within the biotechnology sector is expected to drive the market growth. Enhanced R&D activities have contributed to continuous innovation and improved testing panels,
More news about: Allied Market Research
Apr 24, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace. About HarrowHarrow,
More news about: Nordic Pharma
Apr 24, 2025, 09:09 ET NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today issued a shareholder letter from Chief Executive Officer
More news about: NeuroSense
Apr 24, 2025, 09:00 ET Araceli Biosciences Closes $11.2M Seed Financing to Change the Pace of Drug Discovery
Ore., April 24, 2025 /PRNewswire/ -- Araceli Biosciences, a pioneering biotechnology company revolutionizing high-content imaging and AI-powered analysis, today announced the successful completion of its Seed funding round, raising
More news about: Araceli Biosciences
Apr 24, 2025, 09:00 ET Araceli Biosciences Closes $11.2M Seed Financing to Change the Pace of Drug Discovery
Ore., April 24, 2025 /PRNewswire/ -- Araceli Biosciences, a pioneering biotechnology company revolutionizing high-content imaging and AI-powered analysis, today announced the successful completion of its Seed funding round, raising
More news about: Araceli Biosciences
Apr 24, 2025, 08:30 ET Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a patent infringement lawsuit against Merck Sharp
More news about: Halozyme Therapeutics, Inc.
Apr 24, 2025, 08:00 ET Beacon Therapeutics Announces ARVO 2025 Presentation on Preliminary 6-Month Data from its Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
24, 2025 /PRNewswire/ -- Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announces an upcoming presentation on 6-month
More news about: Beacon Therapeutics
Apr 24, 2025, 08:00 ET Stealth BioTherapeutics to Present New Bevemipretide Data at ARVO Annual Meeting
April 24, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.
Apr 24, 2025, 08:00 ET Alcyone Therapeutics Announces Strategic Financing to Advance an Expanded Pipeline of Pediatric-Focused Precision Therapeutics for Severe Neurological Diseases
NationwideChildrens.org/Research. About Alcyone TherapeuticsAlcyone Therapeutics is a clinical-stage biotechnology company committed to transforming pediatric care through a diversified portfolio of precision CNS therapeutics and dosing platforms. The Company
More news about: Alcyone Therapeutics
Apr 24, 2025, 07:00 ET Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
and has established itself both nationally and internationally. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Apr 24, 2025, 06:00 ET Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering
Apr 24, 2025, 05:45 ET Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact The Gross Law Firm about pending Class Action - SANA
April 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 24, 2025, 02:28 ET Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
The US alone accounts for approximately 40% of this market. About Moebius Medical Moebius Medical is a clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis. The company was founded in 2008 within the RAD Biomed Accelerator to
More news about: Moebius
Apr 23, 2025, 20:00 ET 前Nike副總裁兼總經理Bert Hoyt加入矽響先創dBio，擔任董事會顧問，推動運動與健康科技發展新里程
盧森堡2025年4月24日 /美通社/ -- 矽響先創Decentralized Biotechnology Intelligence Holding Group Inc.（簡稱dBio）身為運動與健康科技領域的領導創新者，致力於提供先進的可穿戴人工智慧物聯網 (AIoT) 解決方案，將運動表現與即時健康數據完美結合。今日榮幸宣布，Hubertus "Bert
More news about: Decentralized Biotechnology Intelligence Holding Group Inc.
Apr 23, 2025, 20:00 ET Former Nike VP & GM Bert Hoyt Joins dBio to Drive Next-Gen Sports & Health Tech as Board Advisor
LUXEMBOURG, April 23, 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading innovator in sports and health tech, delivering advanced wearable AIoT solutions that seamlessly
More news about: Decentralized Biotechnology Intelligence Holding Group Inc.
Apr 23, 2025, 20:00 ET Nike: Ehemaliger Vizepräsident und Geschäftsleiter Bert Hoyt wird Vorstandsberater bei dBio und treibt die Entwicklung der nächsten Generation von Sport- und Gesundheitstechnologien voran
LUXEMBURG, 24. April 2025 /PRNewswire/ -- Die Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), ein führender Innovator im Bereich Sport- und Gesundheitstechnologie, der fortschrittliche tragbare AIoT-Lösungen
More news about: Decentralized Biotechnology Intelligence Holding Group Inc.
Apr 23, 2025, 20:00 ET Former Nike VP & GM Bert Hoyt Joins dBio to Drive Next-Gen Sports & Health Tech as Board Advisor
LUXEMBOURG, April 24, 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading innovator in sports and health tech, delivering advanced wearable AIoT solutions that seamlessly
More news about: Decentralized Biotechnology Intelligence Holding Group Inc.
Apr 23, 2025, 20:00 ET El exvicepresidente y gerente general de Nike, Bert Hoyt, se une a dBio como asesor de la junta directiva
LUXEMBURGO, 24 de abril de 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), un innovador líder en tecnología deportiva y de salud, que ofrece soluciones AIoT portátiles avanzadas que
More news about: Decentralized Biotechnology Intelligence Holding Group Inc.
Apr 23, 2025, 20:00 ET Nike : l'ancien vice-président et directeur général Bert Hoyt rejoint dBio comme conseiller du conseil d'administration pour promouvoir les technologies de pointe en sport et santé
LUXEMBOURG, 24 avril 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), un innovateur de premier plan dans les technologies du sport et de la santé, offrant des solutions AIoT
More news about: Decentralized Biotechnology Intelligence Holding Group Inc.
Apr 23, 2025, 19:00 ET Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the first clinical
More news about: Adcentrx Therapeutics